Status:
COMPLETED
Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma
Lead Sponsor:
Eli Lilly and Company
Conditions:
Mantle-Cell Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purposes of this study are to determine the safety of oral enzastaurin and any side effects that might be associated with it and whether enzastaurin can help participants with mantle cell lymphoma...
Eligibility Criteria
Inclusion
- Mantle cell lymphoma
- Previous treatment for mantle cell lymphoma
- Previously relapsed mantle cell lymphoma with no more than 4 chemotherapy regimens.
- Have discontinued all previous therapies for cancer, except corticosteroids up to 25 milligrams per day (mg/day)
- Adequate organ function
Exclusion
- Inability to swallow tablets
- Must not have significant heart problems
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00088205
Start Date
March 1 2004
End Date
May 1 2008
Last Update
July 1 2020
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Woolloongabba, Queensland, Australia
2
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Parkville, Victoria, Australia
3
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Prahran, Victoria, Australia
4
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Wodonga, Victoria, Australia